Prognostic value of primary tumor surgery in minor salivary-gland carcinoma patients with distant metastases at diagnosis: First evidence from a SEER-based study

Xiao Shi, Nai Si Huang, Rong Liang Shi, Wen Jun Wei, Yu Long Wang, Qing Hai Ji

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: The prognostic value of primary tumor surgery (PTS) in minor salivary-gland carcinoma (MiSGC) with distant metastasis (DM) at diagnosis has never been investigated. In this study, we aimed to provide the first evidence. Patients and methods: The Surveillance, Epidemiology, and End Results (SEER) database was employed to identify MiSGC patients with DM at diagnosis. The prognostic value of PTS was evaluated by Kaplan–Meier methods, log-rank analyses, and multivariate Cox proportional-hazard regression models. Results: Of the 152 eligible patients included in our study, 50 (32.9%) had undergone PTS. Kaplan–Meier analyses showed that the PTS group had >20% increase in 1-and 2-year overall survival (OS) and cancer-specific survival (CSS) compared with their counterparts without PTS (PTS group vs no-PTS group, 1-year OS 66.1% vs 43.9%, 1-year CSS 69.9% vs 44.9%, 2-year OS 56.6% vs 24.2%, 2-year CSS 59.9% vs 25.7%). Compared with the no-PTS group, multivariate analyses also demonstrated a significantly decreased risk of overall mortality (HR 0.601, 95% CI 0.379–0.952; P=0.031) and cancer-specific mortality (HR 0.547, 95% CI 0.336–0.891; P=0.015) in the PTS group. Subgroup multivariate analyses revealed patients with T1–T3 oropharynx, nasal cavity, or paranasal sinus primary MiSGC, especially adenoid cystic carcinoma, might benefit from PTS (all P<0.05). Conclusion: PTS is associated with improved survival in highly selected MiSGC patients and may be considered in future clinical practice. However, prospective studies with larger sample size are still necessary to validate our findings.

Original languageEnglish (US)
Pages (from-to)2163-2172
Number of pages10
JournalCancer Management and Research
Volume10
DOIs
StatePublished - Jan 1 2018

Fingerprint

Minor Salivary Glands
Epidemiology
Neoplasm Metastasis
Carcinoma
Neoplasms
Survival
Multivariate Analysis
Paranasal Sinuses
Adenoid Cystic Carcinoma
Oropharynx
Mortality
Nasal Cavity

Keywords

  • Distant metastasis
  • Minor salivary gland carcinoma
  • Primary site
  • Primary tumor surgery
  • SEER
  • T stage

ASJC Scopus subject areas

  • Oncology

Cite this

Prognostic value of primary tumor surgery in minor salivary-gland carcinoma patients with distant metastases at diagnosis : First evidence from a SEER-based study. / Shi, Xiao; Huang, Nai Si; Shi, Rong Liang; Wei, Wen Jun; Wang, Yu Long; Ji, Qing Hai.

In: Cancer Management and Research, Vol. 10, 01.01.2018, p. 2163-2172.

Research output: Contribution to journalArticle

@article{db459dc1dfca4f0cbd21a4b738e02adf,
title = "Prognostic value of primary tumor surgery in minor salivary-gland carcinoma patients with distant metastases at diagnosis: First evidence from a SEER-based study",
abstract = "Purpose: The prognostic value of primary tumor surgery (PTS) in minor salivary-gland carcinoma (MiSGC) with distant metastasis (DM) at diagnosis has never been investigated. In this study, we aimed to provide the first evidence. Patients and methods: The Surveillance, Epidemiology, and End Results (SEER) database was employed to identify MiSGC patients with DM at diagnosis. The prognostic value of PTS was evaluated by Kaplan–Meier methods, log-rank analyses, and multivariate Cox proportional-hazard regression models. Results: Of the 152 eligible patients included in our study, 50 (32.9{\%}) had undergone PTS. Kaplan–Meier analyses showed that the PTS group had >20{\%} increase in 1-and 2-year overall survival (OS) and cancer-specific survival (CSS) compared with their counterparts without PTS (PTS group vs no-PTS group, 1-year OS 66.1{\%} vs 43.9{\%}, 1-year CSS 69.9{\%} vs 44.9{\%}, 2-year OS 56.6{\%} vs 24.2{\%}, 2-year CSS 59.9{\%} vs 25.7{\%}). Compared with the no-PTS group, multivariate analyses also demonstrated a significantly decreased risk of overall mortality (HR 0.601, 95{\%} CI 0.379–0.952; P=0.031) and cancer-specific mortality (HR 0.547, 95{\%} CI 0.336–0.891; P=0.015) in the PTS group. Subgroup multivariate analyses revealed patients with T1–T3 oropharynx, nasal cavity, or paranasal sinus primary MiSGC, especially adenoid cystic carcinoma, might benefit from PTS (all P<0.05). Conclusion: PTS is associated with improved survival in highly selected MiSGC patients and may be considered in future clinical practice. However, prospective studies with larger sample size are still necessary to validate our findings.",
keywords = "Distant metastasis, Minor salivary gland carcinoma, Primary site, Primary tumor surgery, SEER, T stage",
author = "Xiao Shi and Huang, {Nai Si} and Shi, {Rong Liang} and Wei, {Wen Jun} and Wang, {Yu Long} and Ji, {Qing Hai}",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/CMAR.S172725",
language = "English (US)",
volume = "10",
pages = "2163--2172",
journal = "Cancer Management and Research",
issn = "1179-1322",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Prognostic value of primary tumor surgery in minor salivary-gland carcinoma patients with distant metastases at diagnosis

T2 - First evidence from a SEER-based study

AU - Shi, Xiao

AU - Huang, Nai Si

AU - Shi, Rong Liang

AU - Wei, Wen Jun

AU - Wang, Yu Long

AU - Ji, Qing Hai

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: The prognostic value of primary tumor surgery (PTS) in minor salivary-gland carcinoma (MiSGC) with distant metastasis (DM) at diagnosis has never been investigated. In this study, we aimed to provide the first evidence. Patients and methods: The Surveillance, Epidemiology, and End Results (SEER) database was employed to identify MiSGC patients with DM at diagnosis. The prognostic value of PTS was evaluated by Kaplan–Meier methods, log-rank analyses, and multivariate Cox proportional-hazard regression models. Results: Of the 152 eligible patients included in our study, 50 (32.9%) had undergone PTS. Kaplan–Meier analyses showed that the PTS group had >20% increase in 1-and 2-year overall survival (OS) and cancer-specific survival (CSS) compared with their counterparts without PTS (PTS group vs no-PTS group, 1-year OS 66.1% vs 43.9%, 1-year CSS 69.9% vs 44.9%, 2-year OS 56.6% vs 24.2%, 2-year CSS 59.9% vs 25.7%). Compared with the no-PTS group, multivariate analyses also demonstrated a significantly decreased risk of overall mortality (HR 0.601, 95% CI 0.379–0.952; P=0.031) and cancer-specific mortality (HR 0.547, 95% CI 0.336–0.891; P=0.015) in the PTS group. Subgroup multivariate analyses revealed patients with T1–T3 oropharynx, nasal cavity, or paranasal sinus primary MiSGC, especially adenoid cystic carcinoma, might benefit from PTS (all P<0.05). Conclusion: PTS is associated with improved survival in highly selected MiSGC patients and may be considered in future clinical practice. However, prospective studies with larger sample size are still necessary to validate our findings.

AB - Purpose: The prognostic value of primary tumor surgery (PTS) in minor salivary-gland carcinoma (MiSGC) with distant metastasis (DM) at diagnosis has never been investigated. In this study, we aimed to provide the first evidence. Patients and methods: The Surveillance, Epidemiology, and End Results (SEER) database was employed to identify MiSGC patients with DM at diagnosis. The prognostic value of PTS was evaluated by Kaplan–Meier methods, log-rank analyses, and multivariate Cox proportional-hazard regression models. Results: Of the 152 eligible patients included in our study, 50 (32.9%) had undergone PTS. Kaplan–Meier analyses showed that the PTS group had >20% increase in 1-and 2-year overall survival (OS) and cancer-specific survival (CSS) compared with their counterparts without PTS (PTS group vs no-PTS group, 1-year OS 66.1% vs 43.9%, 1-year CSS 69.9% vs 44.9%, 2-year OS 56.6% vs 24.2%, 2-year CSS 59.9% vs 25.7%). Compared with the no-PTS group, multivariate analyses also demonstrated a significantly decreased risk of overall mortality (HR 0.601, 95% CI 0.379–0.952; P=0.031) and cancer-specific mortality (HR 0.547, 95% CI 0.336–0.891; P=0.015) in the PTS group. Subgroup multivariate analyses revealed patients with T1–T3 oropharynx, nasal cavity, or paranasal sinus primary MiSGC, especially adenoid cystic carcinoma, might benefit from PTS (all P<0.05). Conclusion: PTS is associated with improved survival in highly selected MiSGC patients and may be considered in future clinical practice. However, prospective studies with larger sample size are still necessary to validate our findings.

KW - Distant metastasis

KW - Minor salivary gland carcinoma

KW - Primary site

KW - Primary tumor surgery

KW - SEER

KW - T stage

UR - http://www.scopus.com/inward/record.url?scp=85057603965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057603965&partnerID=8YFLogxK

U2 - 10.2147/CMAR.S172725

DO - 10.2147/CMAR.S172725

M3 - Article

AN - SCOPUS:85057603965

VL - 10

SP - 2163

EP - 2172

JO - Cancer Management and Research

JF - Cancer Management and Research

SN - 1179-1322

ER -